Adolescence is a time of great psychological and physical change. In the UK, girls enter puberty around the age of 10 years with a median age of menarche of 12.9 years; thereafter, it may be several years before regular menstrual cycles are established. Variations in the type and the frequency of periods may create anxiety regarding ill health or serious underlying disorders. With the increase in childhood obesity and subsequent polycystic ovary syndrome, there is a greater awareness and presentation of girls with disorders of menstruation. This review focuses on normal variations of menses and common pathological causes of menstrual problems, including amenorrhoea, dysmenorrhoea and menorrhagia. Further consideration is given to the variations of presentation of polycystic ovary syndrome. It provides a guide to evaluate the various symptoms, investigations and management options.
The normal menstrual cycle is a coordinated sequence of events involving the hypothalamus, pituitary, ovary and uterus and menarche. The onset of menstrual periods is an important landmark refl ecting health and signifying the maturation of reproductive potential.
The defi nition of normal menstrual function and the approach to menstrual disorders differ between adolescents and adults, but currently, there is no consensus on the adolescent age range and a lack of data on the numbers of adolescents with different gynaecological problems. 1 In our experience, they may present to a number of different services, depending on their physical and psychological maturity; thus, it is diffi cult to get an accurate picture of problems in this age group.
NORMAL MENSTRUAL CYCLE
The hypothalamic-pituitary-ovarian (HPO) axis is active during fetal life, quiescent during childhood and then reactivated at puberty after removal of the inhibitory mechanisms that govern the release of gonadotrophin-releasing hormone (GnRH) from the hypothalamus. This results in increased pulsatility of luteinising hormone (LH) and follicle-stimulating hormone (FSH), which are evident approximately 1 year before breast budding. Menarche occurs towards the end of puberty when the complex cascade of hormonal events results in suffi cient ovarian oestrogens to promote endometrial proliferation.
The physiology of the menstrual cycle is shown in fi gure 1. The ovarian cycle is divided into the follicular phase before ovulation and the luteal phase after ovulation. The fi rst day of the menstrual cycle is the fi rst day of menstruation, when oestrogen and progesterone secretions from the ovary are low. Ovulation occurs midcycle in response to high oestrogen and LH levels. Thereafter, the remaining granulosa cells become the corpus luteum that produces progesterone. In the absence of fertilisation or implantation, the corpus luteum degenerates, and progesterone and oestradiol levels fall. In the uterus, the endometrium responds to cyclic oestrogen and progesterone. Here, the proliferative and secretory phases correspond to the follicular and luteal phases in the ovary, respectively. As the oestrogen levels begin to rise, the endometrial cells proliferate, glands enlarge and the endometrium becomes supplied with blood vessels. The secretory phase after ovulation is characterised by progesterone secretion from the corpus luteum; this enables the endometrium to become receptive to a fertilised embryo. However, in the absence of pregnancy, the decrease in oestrogen and progesterone levels cause involution of the endometrium and menstrual loss.
MENARCHE
In the fi rst half of the last century, there was a trend towards a reduction in the age of menarche. This trend has largely remained stable in the Western world for several decades, with a median age of menarche of 12.9 years in the current UK adolescent population with almost one in eight girls attaining menarche while at primary school. 2 It is reported that early menarche may be a risk factor for teenage depression, dysmenorrhoea and breast cancer in adulthood. 3 4 In some racial groups and in children with obesity, a tendency towards earlier puberty persists. 5 6 In 1970, Frisch hypothesised that a minimum weight and fat mass must be achieved before menarche could occur. Although a critical fat mass of 17% of body weight was proposed for menses to occur, there is little evidence for a threshold effect because menarche may occur despite low fat levels. [7] [8] [9] Furthermore, the distribution of fat to the lower body rather than overall body fat may also infl uence the timing of menarche. 10 Conversely, weight gain may be part of the reason that present trends in increasing weight and body mass index (BMI) result in an earlier age of menarche in such females. 11 In a cohort of Australian children, an association between intrauterine and postnatal growth has been shown, with menarche occurring 6 months earlier in girls who had the lowest birth weight and greatest weight gain by 8 years of age. 12 After menarche, it may still take up to 2-3 years to establish regular menstrual cycles. This is because of a lack of ovulation until the mechanism of the oestrogen-induced LH surge is mature and ovulatory cycles can occur. In anovulatory cycles, oestrogen, unopposed by progesterone, produces an unstable endometrial lining that eventually breaks down, leading to irregular uterine bleeding. Initially, most cycles range from approximately 20-45 days. The lower limit of normal at 20 days is consistent across several studies, whereas the upper limit is much more variable at 40-45 days. This is wider than the normal range in adults (24-38 days) . Cycles outside this range are uncommon, even in young girls and may deserve evaluation. 13 Thus, the fi nding of oligomenorrhoea should be interpreted with caution because cycles more >35 days may occur during the fi rst 5 years after the onset of menarche, 14 and generally, there may be little need to consider treatments in healthy teenagers.
ISOLATED PREMATURE MENARCHE
Isolated premature menarche is cyclical vaginal bleeding in the absence of secondary sexual development. This is a diagnosis of exclusion, and investigations reveal a prepubertal GnRH test, normal prepubertal ultrasound scan and lack of identifi able local causes such as the presence of a foreign body, abuse, trauma and local neoplasms. The aetiology is unknown, and the absence of endometrial thickness is against the proposal of increased oestrogen sensitivity. 15 An alternative hypothesis suggests a transient activation of the HPO axis; again, this is not a consistent fi nding. The cyclical bleeding is often transient, or it may continue till the onset of normal puberty; however, it is reassuring that normal pubertal development and the resumption of menstruation occurs at an appropriate age and that future growth and fertility do not appear to be affected. 15 16 AMENORRHOEA Amenorrhoea is the absence of menstruation that may be temporary or permanent. Primary amenorrhoea is a failure to menstruate by the age of 16 years in the presence of normal growth and secondary sexual characteristics. In this group of adolescents, it is estimated that endocrine disorders may account for 40% of the incidence of primary amenorrhoea; and developmental abnormalities, for 60%. 17 Secondary amenorrhoea refers to cessation of menstruation for six consecutive months in females who have attained menarche. In all the girls, a central cause affecting the hypothalamus or the pituitary gland should be considered. As shown in table 1, there is a considerable overlap between the causes of primary and secondary amenorrhoea.
Initially, normal reproductive anatomy should be established with an abdominal and pelvic ultrasound scan, and causes of delayed puberty and chromosomal anomalies should be ruled out. 18 Specifi c investigations should be targeted towards the clinical fi ndings and suspected aetiology, but baseline investigations should include serum gonadotrophins (LH and FSH), which will indicate premature ovarian failure if raised or may suggest hypothalamic amenorrhoea if low. Other tests include prolactin levels to exclude a prolactinoma and thyroid function tests because around 4% of adult women with amenorrhoea may have deranged thyroid function. 19 Hyperandrogenism is a feature of polycystic ovary syndrome (PCOS) and late onset congenital adrenal hyperplasia; therefore, measurements of androgens (17 hydroxyprogesterone, dehydroepiandrosterone sulphate and testosterone) should be taken if there is evidence of hirsutism with oligomenorrhoea/ amenorrhoea, especially in the context of obesity. Some of the biochemical perturbations are indicated in relation to the relevant disorder below.
Eating disorders
Eating disorders are prevalent in adolescent girls with amenorrhoea, and absence of secondary sexual characteristics or menarche may be the primary presentation. Amenorrhoea may even precede signifi cant weight loss. 20 If menarche has been achieved, a detailed menstruation history should include Figure 1 Hormone levels, follicular development and endometrial changes in the normal menstrual cycle. This ovarian follicular stage is characterised by increases in the size of the ovarian follicles and selection of a dominant follicle that progresses to full maturity. Once circulating levels of oestradiol reach a critical concentration, they induce the LH surge that leads to ovulation around day 14 of the menstrual cycle. After ovulation, the remaining granulosa cells become the corpus luteum that produces progesterone.
group.bmj.com on April 21, 2011 -Published by adc.bmj.com Downloaded from the weight at which menses were lost. In adults, a BMI of 18.5 is consistent with anorexia nervosa, but in adolescents, a BMI percentile should be sought. Laboratory fi ndings include low levels of LH, FSH and oestradiol; thus, contributing to hypothalamic amenorrhoea, which may cause the ovaries and the uterus to regress in size. Leptin level, which is produced by the adipocytes and is responsible for regulating energy levels, remains lower in girls with amenorrhoea than in those who resume menses. 21 Furthermore, it appears that kisspeptin (encoded by the KiSS1 gene) in the brain may also be an important signalling pathway that couples energy reserves to normal reproductive function. 22 Two years after nutritional rehabilitation, approximately 95% of patients resume menses. Restoration of the HPO axis can be monitored by measuring serum oestradiol levels. A level of oestrogen >110 pmol/l (30 pg/ml) is predictive of resumption of menses within 3-6 months. 20 Adolescence is also a time of peak bone mass acquisition, and this is disrupted in females with eating disorders, with only around 14% of females in their early 20s having a normal bone density at all sites. 23 The rate of bone loss during active disease may be up to 2.5% a year in females with anorexia nervosa. 24 This may be reversed with weight gain and resumption of menses. Despite this reversal, the overall lower bone mass does persist even after several decades after recovery from the eating disorder. 25 Combined oral contraceptive preparations (COCP) that contain fi xed amounts of oestrogen and progesterone will induce regular menstrual cycles, and these are often used to optimise skeletal health, but randomised placebo-controlled trials have shown little evidence for effect on bone density 26 ; indeed they may mask the resumption of normal menses that are an indicator of recovery of the HPO axis.
Exercise-induced amenorrhoea
Intense physical exertion may have a disruptive effect on both the menstrual cycle and the rate of reproductive development in young women, as athletes tend to attain menarche, on average, later than non-athletes. 27 This varies by sport, position and specialisation within the sport; in particular, a later age at menarche has been reported for girls participating in competitive sports such as track and gymnastics, as well as in artistic athletics such as ballet or dance. 28 Although competitive swimmers have a mean age of menarche similar to that of non-athletes, there is evidence that age at menarche and subsequent athletic performance are related, with a signifi cantly later menarche observed in the more competitive swimmers. This is, therefore, consistent with results from other studies suggesting that female athletes with superior performance experience a later menarche. 27 28 Exercise-induced amenorrhoea or the female athletic triad consists of three interrelated health disorders: disordered eating, menstrual dysfunction and low bone mass. Menstrual dysfunction may be caused by weight fl uctuations, insuffi cient energy availability or stress associated with intense training regimens. All athletes with menstrual irregularity require thorough evaluation to rule out serious pathological conditions because the diagnosis of exerciseassociated menstrual dysfunction can be made only by excluding other aetiological factors. The prevalence of menstrual dysfunction in adolescent athletes has been reported by Nichols et al 29 in 2006. Of 170 adolescent athletes, 23.5% had menstrual irregularity, 17% had oligomenorrhoea, 5.3% had secondary amenorrhoea and 1.2% had primary amenorrhoea. The age at menarche occurred later, and the prevalence of primary amenorrhoea was higher in elite athletes than in controls and dependent on the type of physical activity. 30 The treatment of exercise-induced amenorrhoea shares many parallels with eating disorders. The focus is to correct the negative energy balance and restore normal menstrual function. This should re-establish the GnRH and LH pulsatility and menstruation. The benefi ts on bone conferred by sports participation may be negated in young athletes with menstrual dysfunction. Hormone replacement therapy and COCP are not commonly recommended in athletes with the athletic triad because restoring regular menstruation has not been shown to increase bone mineral density and only at best has been shown to halt further bone mineral loss. 31 
HEAVY PERIODS
Menorrhagia refers to menstrual loss ≥80 ml. 32 Assessing the amount of blood loss is diffi cult for the adolescent and the clinician. In practical terms, menstrual loss requiring pad or tampon changes every 1-2 h with anything longer resulting in "accidents" is generally considered excessive, particularly if the menses last 8 or more days. 33 Alternatively, a pictorial blood loss assessment may also be a useful method of assessing blood loss. 34 It is important to bear in mind that heavy bleeding may be the fi rst presentation of a bleeding disorder. Of 106 teenagers presenting with heavy periods to one paediatric hospital, 13 were found to have a haemoglobin concentration of <10 g/dl, and 23% of these had a bleeding disorder. 35 The reported prevalence of bleeding disorders in adolescents with menorrhagia varies between 10.4% and 48%, with platelet-related problems (thrombocytopenia and platelet function disorders) and the von Willebrand disease making up most of these. 35 36 There are no studies specifi cally tackling the issue of heavy menses in adolescents. Evidence from the Cochrane database demonstrates that menstrual loss may be reduced by 30% and 50% in women taking non-steroidal anti-infl ammatory drugs (NSAIDs) or an antifi brinolytic (such as tranexamic acid), respectively. 37 Approximately a third of patients report adverse effects with antifi brinolytics, which are dose dependent and mainly gastrointestinal in nature, with symptoms including nausea, vomiting and diarrhoea. These can be minimised if medication is limited to the fi rst 3 days of menstruation, which is when 90% of blood loss occurs. 38 39 Concerns about increased thrombotic activity have been raised in patients on tranexamic acid, but epidemiological studies have not indicated such an association. 39 The use of the contraceptive pill (OCP) may reduce menstrual loss by 43%, 40 and this has the benefi t that it may be given in three to four continuous cycles before a 7-day pill-free interval to allow menstruation when convenient for the adolescent. Menorrhagia has also been treated with norethisterone, which is a progesterone derivative and is taken for up to 10 days to arrest bleeding; however, it may cause bloating and fl uid retention, and it does not appear to be any benefi t over the above treatments with NSAIDs and antifi brinolytics. 41 It has, however, been used to delay menstruation for special circumstances if started 3 days before the expected onset of menstruation, which then occurs several days after withdrawal of the progesterone.
PAINFUL PERIODS
Dysmenorrhoea is the most common gynaecological complaint and the leading cause of recurrent short-term school or work absenteeism among female adolescents. 42 Primary dysmenorrhoea is a frequent fi nding in adolescents with a frequency of up to 80%. 43 It becomes more prevalent during late adolescence, and the severity of the symptoms correlates with the onset of ovulatory cycles and with increased duration and amount of menstrual fl ow. 44 In primary dysmenorrhoea, no pelvic pathological feature is identifi ed: an infl ammatory response, mediated by prostaglandins and leukotrienes, causes lower abdominal cramps and systemic symptoms such as nausea, vomiting, bloating and headaches. These typically accompany the start of menstrual fl ow or occur a few hours before or after onset and last for the fi rst 24-48 h.
In about 10% of adolescents with dysmenorrhoea, the painful menstruation is associated with pelvic abnormalities (secondary dysmenorrhoea). Endometriosis is the most common cause of chronic pelvic pain in adolescents, affecting up to 70% of girls with chronic pelvic pain unresponsive to medical management. 17 In adolescents with painful periods, the possibility of reproductive tract anomalies must also be considered. In particular, girls with an early onset of severe dysmenorrhoea beginning with (or even before) menarche should be evaluated to rule out a complete or partially obstructive anomaly, such as longitudinal or transverse vaginal septum. Other causes of pain may originate from any of the pelvic structures.
NSAIDs are the most common pharmacological treatment of dysmenorrhoea because they result in a reduction of prostaglandin production that then results in less vigorous contractions of the uterus. Treatment with NSAIDs is most effective if started 1-2 days before the onset of menses. Adolescents who cannot predict the initiation of their period should be instructed to start NSAIDs as soon as they have any menstruation-associated symptoms.
Although all NSAIDs appear to provide superior pain relief as compared with placebo and paracetamol, there is little evidence to suggest that any particular NSAID is more effective at providing symptomatic relief. 45 They are, however, more likely to cause adverse effects such as indigestion and drowsiness, and it is recommended that they be taken with food.
If the dysmenorrhoea is unresponsive to NSAIDs, the COCP may be offered. This is a widely used treatment to prevent or lessen pain directly by limiting endometrial growth and indirectly by inhibiting ovulation and subsequent progesterone secretion. A continuous COCP cycle allowing menstruation to occur three or four times a year may be considered because it has been shown to be well tolerated and effi cacious in reducing menstrual symptoms in women. 46 It is important to consider, however, that taking the OCP may not be acceptable to many families, particularly those with religious or cultural reservations, and this situation needs to be handled sensitively. Often emphasising the hormonal nature of the treatment and explaining the regulation of the cycles may help to alleviate these concerns. If medical management fails, then evaluation for secondary causes of dysmenorrhoea should commence. Occasionally, adolescents may have a psychogenic component as part of their dysmenorrhoea. In particular, a history of physical or sexual abuse has been associated with chronic pelvic pain. 47 
POLYCYSTIC OVARY SYNDROME
Polycystic ovary syndrome is one of the commonest endocrinological disorders during adolescence. 48 The Rotterdam consensus requires two of the following three features to make a diagnosis of PCOS: oligomenorrhoea/amenorrhoea, hyperandrogenism and polycystic ovaries. 49 Thus, polycystic ovaries are indicative of but not diagnostic of PCOS because they may be seen in the healthy female population.
Puberty is associated with a state of insulin resistance, 50 and in the early phase of puberty, there are relatively high levels of androgens compared with estrogens. 51 Thus, the key features of this condition, hyperinsulinism and hyperandrogenaemia, are also present during normal physiological development. Furthermore, the oligomenorrhoea in this age group may be diffi cult to distinguish from physiological anovulation in the fi rst two postmenarcheal years from PCOS. The onset of PCOS is during adolescence or soon after menarche, and individuals may present with menstrual irregularity or primary or secondary amenorrhoea. Currently, there are no validated criteria for PCOS in the adolescent population. Based on clinical criteria alone, there is a reported incidence of 3% in one cross-sectional study of adolescents, 52 but this is likely to be higher if hormonal assessments had been included. Delaying a diagnosis of PCOS till 2 years after menarche has been postulated by de Zegher and Ibáñez 53 in an effort to prevent an overdiagnosis of PCOS, but this may present diffi culties in girls in whom primary amenorrhea may be the presenting feature of PCOS.
PCOS is a heterogeneous condition, and genetic and environmental factors have been implicated in the development of PCOS, with the highest prevalence of 52% in South Asian women living in the UK. 54 55 The pathophysiological and physical manifestations of PCOS are represented in fi gure 2. Most women with PCOS, regardless of weight, have a form of insulin resistance, and this is one of the hallmarks of this syndrome. Insulin impedes ovulation, either by directly affecting follicular development or by indirectly increasing ovarian androgen levels or altering gonadotrophin secretion. 56 The LH tends to be raised in PCOS because rapid GnRH pulse frequency favours pituitary secretion of LH, resulting in elevated LH:FSH ratios. This high LH stimulates ovarian androgen production, whereas relative defi ciency of FSH impairs aromatisation of oestradiol and follicular development, contributing to ovulatory dysfunction (fi g 2).
Hyperandrogenism is the other major feature of PCOS and clinically manifests itself as hirsutism, acne or, more rarely, androgenic alopecia. The excess hair growth is at androgen-dependent sites such as the upper lip, chin, neck and or abdomen and may be more prevalent in some populations. 57 This is in contrast to hypertrichosis, which refers to a generalised increase in body hair and is not androgen dependent. Clinically, the degree of hirsutism can be assessed by using the Ferriman-Gallwey scoring scale that provides a numerical value for excess hair in nine body areas. This scale was standardised in a population of adult Caucasian women 58 and may be less accurate for use in adolescents especially because hirsutism varies with ethnicity and puberty. 59 It is not clear whether the hyperandrogenaemia causing the hirsutism in PCOS is the result or the cause of hyperinsulinism. 60 The cause of the hirsutism is likely to be multifactorial in origin, with hyperinsulinaemia inhibiting the hepatic production of sex hormone-binding globulin (SHBG), causing increased free-circulating androgen levels. 61 The effects of
prenatal androgen exposure that, in animal models at least, appears to disrupt the hypothalamic-pituitary-adrenal axis 62 has not been demonstrated in a recent report in adolescents with PCOS who were exposed to maternal and fetal hyperandrogenemia. 63 It is likely that an early intrauterine environment that predisposes to low birth weights, followed by childhood weight gain, have an infl uence on adrenarche, earlier menarche and PCOS. Low birth weight has been demonstrated as a risk factor for premature adrenarche and thus PCOS, 64 with an increased risk in the most severely growth restricted groups. The studies of Ibanez et al 65 have provided a link between premature adrenarche and the development of PCOS during adolescence and made a connection between central adiposity and hyperinsulism; however, it is important to note that their cohort of girls at risk for PCOS were not obese. 66 The fi ndings of these elegant long-term studies have not been corroborated by Meas et al. 67 In their cohort of adolescents with premature adrenache, there was no difference in hirsutism, acne, menstrual irregularity and insulin levels, and only up to 20% of there population developed hyperandrogenism. Similarly, the association between low birth weight and PCOS has not been consistent across study populations. 68 How the risk factors for PCOS such as birth weight, childhood weight gain and physiological changes at puberty, in addition to a genetic predisposition, interrelate with one another remains an area of intense study. Some of the data is confl icting and could be because of the population studied, the defi nition of PCOS used and variations in the biochemical assays. This should, however, not detract from the fact the PCOS has a number of important metabolic consequences, and recognition of these may allow targeted lifestyle changes and treatments.
The menstrual irregularities are one end of a spectrum of diffi culties that females may face in adolescence because they will be prone to infertility, endometrial carcinoma and the development of the metabolic syndrome that also includes diabetes, dyslipidaemia and hypertension. 69 Interestingly, PCOS is the only cause of amenorrhoea that does not predispose to osteoporosis. As there is a signifi cantly higher prevalence of metabolic syndrome in adolescents with PCOS, 70 it is imperative to evaluate adolescents with menstrual disturbance because this may be the fi rst presentation of a metabolic derangement.
The mainstay of treatment is to control obesity because this will improve the symptoms and the endocrine profi le. Thereafter, the specifi c treatment focuses on the symptomatic management of the reproductive, metabolic and cosmetic manifestations of this disorder (fi g 2).
The hyperinsulinism has been treated with insulinsensitising agents such as metformin, but its effi cacy is still uncertain. In a recent Cochrane review, metformin improved pregnancy and ovulation rates in women but not live births, and it had limited effects on weight loss and metabolic parameters. 71 It did, however, reduce fasting insulin levels in the nonobese females only (BMI <30 kg/m 2 ). 71 Therefore, its routine use cannot be routinely recommended until further studies in this age group have been undertaken. 72 In females with anovulatory cycles, the unopposed action of oestrogen on the endometrium (due to a lack of cyclical progesterone) may result in endometrial hyperplasia and endometrial cancer in the following decades. Thus, it is important to induce a menstrual bleed at least every 3 months in these adolescents with oligomenorrhoea. 17 The easiest way to regulate the menstrual cycle is the use of COCPs, which are often considered fi rst-line therapy for adolescents because they restore regular menses and may ameliorate the effects of androgen excess via oestrogen-mediated increases in hepatic production of SHBG and suppression of LH-driven ovarian androgen production. Studies treating adolescents with a variety of COCPs have shown improvements in androgen levels and menstrual irregularity and reduction of hirsutism. 73 Other studies, however, have suggested that COCPs may potentially exacerbate the metabolic features of PCOS, including insulin resistance, obesity and metabolic syndrome. 74 They are associated with an increase in the relative risk of cardiovascular events in the general female population, but the risk among women in PCOS is unknown. 75 The hyperandrogenism in PCOS may also be treated with the addition of an antiandrogen agent. A commonly used preparation is Dianette (a combination of ethinylestradiol 35 μg and cyproterone acetate 2 mg). The latter acts as a competitive inhibitor at the androgen receptor, lowering the levels of androgens and gonadotrophins and increasing SHBG levels; however, it may have effects on lipid metabolism and liver function and is implicated in depression. Because of the long growth cycle of terminal hair, the improvement in hirsutism may take up to 6 months to become apparent 76 and treatment may need to continue for several years or until signifi cant weight loss has been achieved. 77 Alternatively, a newer preparation such as Yasmin (ethinylestradiol 30 μg and drospirenone 3 mg) may also be used because it achieves good menstrual cycle control and more specifi cally improves acne after 6 months of treatment. 78 The drospirenone in this compound is derived from spironolactone and has antimineralocorticoid and antiandrogenic effects.
Our personal practice is to address lifestyle changes and consider symptomatic treatment. There is little evidence to guide the clinician towards prophylactic treatment of the various manifestations of PCOS. Although metformin treatment may improve the metabolic parameters during puberty, the effects subside after discontinuation of therapy. 79 The current treatment options for various facets of PCOS are covered more comprehensively by Harwood et al. 80 
SUMMARY
▶ Disorders of menstruation can be due to physical or environmental factors or a combination of these, and it is important to evaluate the chromosomal, biochemical and anatomical contributions for the young woman who has problems with her periods, especially because these may have implications for reproductive, endocrine and metabolic disturbances in later life. ▶ Adolescence is a time of increasing physical and psychological maturity, and menarche represents a signifi cant landmark in this transition to adulthood. Regular menstrual cycles may be regarded as a biological marker of female health, but it is important to note that the menstrual cycle may be irregular in the fi rst few postmenarcheal years owing to anovulatory cycles. It may be a distressing time for many girls, often already subject to self-doubt and dissatisfaction with their appearance, which is compounded by social and media pressures. Menarche, dysmenorrhoea, hirsutism, obesity, acne, possibly even fears of pregnancy or infertility all serve to make this time of life a particularly diffi cult one, and it is imperative that the clinician faced with the worried adolescent and the family deals with these issues with sensitivity. Close working relations and clear referral pathways between the departments of paediatric medicine, endocrinology and adult reproductive medicine are essential to ensure the timely investigation and management of these female adolescents.
